Examples of 'investigator-assessed' in a sentence
Meaning of "investigator-assessed"
investigator-assessed (verb): In the context of research or studies, this phrase refers to evaluations, judgments, or assessments made by the individual or team conducting the investigation or analysis
How to use "investigator-assessed" in a sentence
Basic
Advanced
investigator-assessed
The primary endpoint in this study was investigator-assessed overall response rate ORR.
Investigator-assessed progression free survival ( PFS ) was an exploratory endpoint which was not type 1 error controlled.
A clinically significant advantage in investigator-assessed PFS for sunitinib over placebo was observed.
Investigator-assessed Myeloma response n.
Key secondary efficacy outcome measures were investigator-assessed ORR and PFS.
Efficacy assessments included investigator-assessed ORR, retrospectively evaluated by an IRRC, and duration of response.
Other efficacy outcome measures included overall survival ( OS ) and investigator-assessed objective response rate ( ORR ).
The results for investigator-assessed PFS were similar to those observed for IRF-assessed PFS.
Secondary efficacy assessments included investigator-assessed ORR and PFS.
The results for investigator-assessed PFS were comparable to those observed for IRF-assessed PFS.
Objective response ( complete response + partial response ) was investigator-assessed according to RECIST 1.0.
The median estimate for investigator-assessed PFS was 9.9 months for the Cotellic plus vemurafenib arm vs.
Key secondary efficacy outcome measures were investigator-assessed PFS and objective response rate ORR.
Data for investigator-assessed PFS and objective response rate ( ORR ) were also collected.
Key secondary efficacy outcome measures were investigator-assessed objective response rate ( ORR ) and progression-free survival PFS.
See also
Investigator-Assessed mBCC laBCC.
Efficacy results based on investigator-assessed ORR are presented in Table 15 below.
Investigator-assessed PFS months.
The primary endpoint of the study was investigator-assessed PFS evaluated according to RECIST 1.1.
Table 4, Investigator-assessed progression-free survival in patients with previously treated CLL in MURANO.
Change in Composite Investigator-Assessed Symptom Score at 2 hours.
Time to Investigator-Assessed.
Kaplan-Meier curves of investigator-assessed PFS from the updated efficacy analysis are shown in Figure 1.
Efficacy results based on investigator-assessed response rates at week 12 are presented in Table 10 below.
